Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0697

-0.4%

3:55 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LT2011 who wrote (11606)	10/18/2012 8:34:30 PM
From: NTTG	1 Recommendation of 13111

My best guess would be: if they get notification tomorrow, first patient in would be some time between mid Q1-early Q2 2013 (Might be able to squeak a patient into an existing study site if their IRB is willing to consider an expedited review, but that would just be for show). The number of proposed subjects has fallen from ~300 to ~180, but the patient scope has narrowed to stage III w/o rapid progressive disease, so time to full recruitment may shorten a bit, but probably not much more than 6 months or so (these patients are likely in high demand for other clinical trials at busy study centers). Time allocated to the remaining steps should be the same, although I would now allow a longer time line between last patient datapoint collection and final application for market approval. Stunning that it took them 2 years to lock data from the PII, and this long for any news about their PIII attempts..submitted, rejected, still writing? Interesting that the LPC deal has a guard rail around minimum price, don't blame LPC...will be curious to see what the next finance move will be...reach for the shares on the shelf?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next